









## References

1. Green RM, Flamm S. AGA Technical review on the evaluation of liver chemistry tests. *Gastroent*. 2002;123:1367-1384.
2. Minuk GY. Canadian Association of Gastroenterology Practice Guidelines: Evaluation of abnormal liver enzyme tests. *Can J Gastroenterol*. 1998;12:417-21.
3. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *New Engl J Med*. 2000;342:1266-71.
4. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. *Can Med Assoc J*. 2005;172:367-79
5. Storr JG. The Interpretation of abnormal liver tests. *Nutrition*. 2008;24:503.
6. Canadian Blood Services. [www.bloodservices.ca](http://www.bloodservices.ca) c1998-2011 cited 2011; May 30. Available from [http://www.bloodservices.ca/CentreApps/Internet/UW\\_V502\\_MainEngine.nsf/page/E\\_Hepatitis?OpenDocument](http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/page/E_Hepatitis?OpenDocument)
7. Goessling W, Friedman LS. Increased liver chemistry in an asymptomatic patient. *Clin Gastroent and Hepatol*. 2005;2:852-585.
8. Lewis JH, Ahmed M, Shobassy A, et. al. Drug-induced liver disease. *Current Opin Gastroen*. 2006;22:223-233.
9. Bjornsson E. Review article: drug-induced liver injury in clinical practice. *Aliment Pharmacol Ther*. 2010;32:3-13.
10. Kaplowitz N. Drug-induced liver injury. *Clin Infect Dis*. 2004;38 Suppl 2:S44-8.
11. Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. *Hepatology*. 2010;52:2065-76.
12. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. *Am Fam Physician*. 2005;71(6):1105-1110.
13. Hirshfeld GM. & Alexander GJ. Gilbert syndrome: an overview for clinical biochemists. *Ann Clin Biochem*. 2006;43:340-343.
14. Pascale A, Pais R, Ratzu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. *J Gastrointestin Liver Dis*. December 2010;19 (4) 415-423.

This guideline is based on scientific evidence current as of the Effective Date.

This guideline was developed by the Guidelines and Protocols Advisory Committee, approved by the British Columbia Medical Association and adopted by the Medical Services Commission.

### The principles of the Guidelines and Protocols Advisory Committee are to:

- encourage appropriate responses to common medical situations
- recommend actions that are sufficient and efficient, neither excessive nor deficient
- permit exceptions when justified by clinical circumstances

### Contact Information

Guidelines and Protocols Advisory Committee  
PO Box 9642 STN PROV GOVT  
Victoria BC V8W 9P1  
E-mail: [hlth.guidelines@gov.bc.ca](mailto:hlth.guidelines@gov.bc.ca)  
Web site: [www.BCGuidelines.ca](http://www.BCGuidelines.ca)

## DISCLAIMER

The Clinical Practice Guidelines (the "Guidelines") have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give a understanding of a clinical problem and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems. **We cannot respond to patients or patient advocates requesting advice on issues related to medical conditions. If you need medical advice, please contact a health care professional.**